Quantitative HBeAg varies across the different phases of HBV infection, and can predict treatment outcome in the setting of HBV-reactivation driven by iatrogenic immunosuppression

Authors :: C.F. Perno
A. Iuvara
Carlotta Cerva
Sandro Grelli
Mario Angelico
Carla Fontana
V. Svicher
Mohammad Alkhatib
R. Salpini
Aldo Bertoli
L. Sarmati
Mario Starace
M. De Cristofaro
F. Ceccherini Silberstein
Nicola Coppola
L. Piermatteo
Giuseppina Cappiello
Mariantonietta Pisaturo
Carmine Minichini
M. Andreoni
Source :: Digestive and Liver Disease. 52:e21-e22
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Hepatology
HBeAg
business.industry
medicine.medical_treatment
Immunology
Treatment outcome
Gastroenterology
medicine
Hbv reactivation
Immunosuppression
business

Tools